As of this morning – Friday April 23 – the current recorded case count for COVID-19 (coronavirus) in the UK has hit 138,078 with 18,738 deaths.
The National Institute of Health and Care Excellence (NICE) has published new rapid COVID-19 guidelines covering the management of disorders of the digestive system treated with drugs that affect the immune response, and the care of people in hospital who develop heart problems as a consequence of COVID-19 infection.
The guideline on gastrointestinal and liver conditions provides clinicians with advice on how to adjust care to reduce patients’ exposure to COVID-19 and how to balance the risks and benefits of taking drugs that affect the immune response during the pandemic.
It recommends that patients not known to have COVID-19 continue to take existing courses of drugs that affect the immune response to minimise the risk of a flare-up. However, if a patient develops coronavirus symptoms, it’s recommended that they contact their clinical team to get advice about any drugs they are taking.
Clinicians should then discuss the risks and benefits of stopping treatment with the patient or their parents or carers taking into account factors such as the severity of the COVID-19, the severity of their condition and other risk factors such as age and other health conditions.
The guideline on acute myocardial injury aims to help healthcare professionals who are not cardiology specialists to identify, monitor and treat heart problems in adults with known or suspected COVID-19 but without known pre-existing heart disease.
Acute myocardial injury was observed in 9.5% of all hospitalised patients dying in Italy with COVID-19 and that some of the symptoms are similar to the respiratory complications of COVID-19, such as chest pain, heart palpitations, severe tiredness and shortness of breath.
For all patients with a suspected or confirmed myocardial injury, clinicians should monitor the patient’s blood pressure, heart rate and fluid balance. Continuous ECG monitoring, to measure the heart’s electrical activity, is also recommended.
The guidance advises clinicians to be aware that treatments that may be used in COVID-19 clinical trials, such as azithromycin and hydroxychloroquine, may lead to an abnormal heartbeat (arrhythmia).
The Institute’s rapid COVID-19 guidelines are being produced in collaboration with NHS England/Improvement and a cross-specialty clinical group, supported by the specialist societies and Royal Colleges.